Publication Date:
2013-06-06
Description:
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia Leukemia 27, 1254 (June 2013). doi:10.1038/leu.2012.352 Authors: H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, D Beelen, V Vucinic, T Burmeister, M Stelljes, C Faul, P Dreger, A Kiani, K Schäfer-Eckart, R Schwerdtfeger, E Lange, B Kubuschok, H A Horst, M Gramatzki, P Brück, H Serve, D Hoelzer, N Gökbuget & O G Ottmann
Keywords:
minimal residual diseasetyrosine kinase inhibitorPhiladelphia chromosomeBCR–ABL1
Print ISSN:
0887-6924
Electronic ISSN:
1476-5551
Topics:
Medicine
Permalink